Shares of Amgen Inc. (NASDAQ:AMGN – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twenty-four research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $332.55.
A number of equities analysts have recently issued reports on AMGN shares. Bank of America increased their target price on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Dbs Bank upgraded Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Barclays boosted their target price on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Sanford C. Bernstein initiated coverage on shares of Amgen in a report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price target for the company. Finally, Truist Financial downgraded shares of Amgen from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $320.00 to $333.00 in a report on Monday, October 14th.
Get Our Latest Report on Amgen
Amgen Price Performance
Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The firm had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. During the same quarter last year, the business posted $5.00 EPS. The firm’s revenue was up 20.1% on a year-over-year basis. Equities analysts predict that Amgen will post 19.49 earnings per share for the current year.
Amgen Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.84%. Amgen’s dividend payout ratio is currently 128.57%.
Hedge Funds Weigh In On Amgen
Several institutional investors and hedge funds have recently modified their holdings of the company. Hoxton Planning & Management LLC increased its stake in Amgen by 5.7% in the first quarter. Hoxton Planning & Management LLC now owns 739 shares of the medical research company’s stock valued at $210,000 after purchasing an additional 40 shares during the last quarter. First Financial Corp IN increased its stake in shares of Amgen by 15.7% during the 1st quarter. First Financial Corp IN now owns 390 shares of the medical research company’s stock valued at $111,000 after acquiring an additional 53 shares during the last quarter. Sound Income Strategies LLC boosted its position in shares of Amgen by 17.4% in the first quarter. Sound Income Strategies LLC now owns 1,080 shares of the medical research company’s stock worth $307,000 after acquiring an additional 160 shares during the last quarter. Elevated Capital Advisors LLC boosted its position in shares of Amgen by 8.0% in the first quarter. Elevated Capital Advisors LLC now owns 1,328 shares of the medical research company’s stock worth $378,000 after acquiring an additional 98 shares during the last quarter. Finally, Sovereign Financial Group Inc. increased its position in Amgen by 11.0% during the first quarter. Sovereign Financial Group Inc. now owns 1,451 shares of the medical research company’s stock worth $413,000 after purchasing an additional 144 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Read More
- Five stocks we like better than Amgen
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- How to Calculate Stock Profit
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Where Do I Find 52-Week Highs and Lows?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.